ClinicalTrials.govpublic full text
An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
generalized myasthenia gravis (gmg), ea5, generalized myasthenia gravis, complement c5 inhibitor, phase ib, anti-achr, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 876868
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.